A New Class of Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Structure-Activity Relationships for a Series of 9-Alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the Identification of CEP-5214 and Its Dimethylglycine Ester Prodrug Clinical Candidate CEP-7055

Journal of Medicinal Chemistry

Volumn 46, Issue 25, 2003, Pages 5375-5388

  Gingrich, Diane E ^a   Reddy, Dandu R ^a   Iqbal, Mohamed A ^a   Singh, Jasbir ^a   Aimone, Lisa D ^a   Angeles, Thelma S ^a   Albom, Mark ^a   Yang, Shi ^a   Ator, Mark A ^a   Meyer, Sheryl L ^a   Robinson, Candy ^a   Ruggeri, Bruce A ^a   Dionne, Craig A ^a   Vaught, Jeffry L ^a   Mallamo, John P ^a   Hudkins, Robert L ^a  

^a CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; 9 METHYL 12 (3 HYDROXYPROPYL)INDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5 ONE; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN RECEPTOR; CARBAZOLE DERIVATIVE; CP 547 632; DIMETHYLGLYCINE ESTER; INEDENOPYRROLOCARBAZOLE; JANUS KINASE; PRODRUG; PROTEIN CDK1; PROTEIN KINASE C; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE A; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR TYROSINE KINASE INHIBITOR; VATALANIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CARBAZOLES; CELLS, CULTURED; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMANGIOSARCOMA; HUMANS; INDENES; LIVER; MALE; MICE; MICE, NUDE; MODELS, MOLECULAR; PHOSPHORYLATION; PRODRUGS; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SARCOSINE; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 10744227153     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0301641     Document Type: Article

References (48)

1. Folkman, J. Angiogenesis-dependent diseases. Semin. Oncol. 2001, 28, 536-542.
2. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
3. Griffloen, A. W.; Molema, G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 2000, 52, 237-268.
4. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1, 27-31.
5. Fan, T. P. D.; Jaggar, R.; Bicknell, R. Controlling the vasculature: angiogenesis, anti-angiogenesis, and vascular targeting of gene therapy. Trends Pharmacol. Sci. 1995, 16, 57-66.
6. Gimbrone, M. Receptor tyrosine kinase as targets for inhibition of angiogenesis. Drug Discovery Today 1997, 2, 50-63.
7. (a) Thomas, K. A. Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem. 1996, 271, 603-606.
8. (b) Ferrara, N.; Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18, 4-25.
9. (c) Klagsburn, M.; Moses, M. A. Molecular angiogenesis. Chem. Biol. 1999, 6, R217-R227.
10. (a) Salvern, P.; Heikkila, P.; Joensuu, H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br. J. Cancer 1997, 76, 930-934.
11. (b) Shibusa, T.; Shijubo, N.; Abe, S. Tumour angiogenesis and vascular endothelial growth factor expression in stage I lung adrenocarcinoma. Clin. Cancer Res. 1944, 4, 1483-1487.
12. (c) Okita, S.; Kondoh, S.; Shiraishi, K.; Kaino, S.; Hatano, S.; Okita, K. Expression of vascular endothelial growth factor correlates with tumour progression in gallbladder cancer clinical studies. Int. J. Oncol. 1998, 12, 1013-1018.
13. (d) Abdulrauf, S. I. Edvardsen, K.; Ho, K. L.; Yang, X. Y.; Rock, J. P.; Rosenblum, M. L. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low grade astrocytoma. J. Neurosurg. 1998, 88, 513-520.
14. Neufeld, G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13, 9-22.
15. Rahim, N.; Dayanir, V.; Lashkari, K. Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 modulates mitogenic activity of VEGF-R2 in endothelial cells. J. Biol. Chem. 2000, 275, 16986-16992.
16. Gille, H.; Kowalski, J.; Li, B.; LeCouter, J.; Moffat, B.; Zioncheck, T. F.; Pelletier, L.; Ferrara, N. Analysis of biological effects and signaling properties of Flt-1 (VEGF-R1) and KDR (VEGF-R2). J. Biol. Chem. 2001, 276, 3222-3230.
17. (a) Korpelainen, E. I.; Alitalo, K. Signaling angiogenesis and lymphangiogenesis. Curr. Opin. Cell Biol. 1998, 10, 159-164.
18. (b) Kukk, E.; Lymboussaki, A.; Taira, S.; Kaipainen, A.; Jeltsch, M.; Joukov, V.; Alitalo, K. VEGF-C receptor binding and pattern of expression with VEGF-R3 suggests a role in lymphatic vascular development. Development 1996, 122, 3829-3837.
19. Folkman, J. In Cancer Medicine, 5th ed.; Holland, J. E., Frei, I. E., Bast, J., Kufe, D., Pollock, R., Weichselbaum, R., Eds.; B. C. Dekker, Inc.: Ontario, Canada, 2000; pp 132-152.
20. (a) Deplanque, G.; Harris, A. L. Anti-angiogenic agents: clinical trial design and therapies in development. Eur. J. Cancer 2000, 36, 1713-1724.
21. (b) Cristofanilli, M.; Charnsangavej, C.; Hortobagyi, G. N. Angiogenesis Modulation in Cancer Research: Novel Clinical Approaches. Nat. Rev. Drug Discovery 2002, 1, 415-426.
22. (c) Sepp-Lorenzino, L.; Thomas, K. A. Expert Opin. Invest. Drugs 2002, 11, 1-18.
23. Sun, L.; McMahon, G. Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors. Drug Discovery Today 2000, 5, 344-354.
24. (a) Drevs, J.; Muller-Driver, R.; Wittig, C.; Fuxius, S.; Esser, N.; Hugenschmidt, H.; Konerding, M. A.; Allegrini, P. R.; Wood, J.; Hennig, J.; Unger, C.; Marine, D. PTK787/ZK222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, effects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 2002, 62, 4015-4022.
25. (b) Baker, C. H.; Solorzano, C. C.; Fidler, I. J. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. 2002, 62, 1996-2003.
26. (c) Bold, G.; Altman, K.-H.; Frei, J.; Lang, M.; Manley, P. W.; Traxler, P.; Weitfeld, B.; Bruggen, J.; Buschdunger, E.; Cozens, R.; Ferrari, S.; Furet, P.; Hofmann, F.; Martiny-Baron, G.; Mestan, J.; Rosel, J.; Sills, M.; Stover, D.; Acemoglu, F.; Boss, E.; Emmenegger, R.; Lasser, L.; Masso, E.; Roth, R.; Schlachter, C.; Vetterli, W.; Wyxx, D.; Wood, J. M. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinase useful as antagonists of tumor-driven angiogenesis. J. Med. Chem. 2000, 43, 2310-2323.
27. (a) Hennequin, L. F.; Stokes, E. S.; Thomas, A. P.; Johnstone, C.; Ple, P. A.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curwen, J. O. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 2002, 45, 1300-1312.
28. (b) Wedge, S. R.; Ogilvie, D. J.; Dukes, M.; Kendrew, J.; Chester, R.; Jackson, J. A.; Boffey, S. J.; Valentine, P. J.; Curwen, J. O.; Musgrove, H. L. ; Graham, G. A.; Hughes, G. D.; Thomas, A. P.; Stokes, E. S. E.; Curry, B.; Richmond, G. H. P.; Wadsworth, P. F.; Bigley, A. L.; Hennequin, L. F. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002, 62, 4645-4655.
29. Jani, J. P.; Beebe, J. S.; Emerson, E.; Gant, T.; Goodwin, P.; Higdon, C.; Hillerman, S.; Intrieri, C.; Knauth, L.; Marx, M.; Noe, M.; Rossi, A. M.; Savage, D.; Atherton, J.; Floyd, E.; Harriman, S.; Roberts, G. CP-547,632, a novel VEGF-R2 tyrosine kinase inhibitor for cancer therapy. Proc. Am. Assoc. Cancer Res. 2002, 43, 5354.
30. (a) Gingrich, D. E.; Hudkins, R. L. Selected fused pyrrolocarbazoles. Patent WO 0217914, 2002.
31. (b) Pili, R.; Robinson, C.; Morris, C. A.; Dionne, C. A.; Isaacs, J. T.; Ruggeri, B. A. CEP-5214, a novel orally-active inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, inhibits VEGF-induced angiogenesis and prostate tumor growth in vivo. Clin. Cancer Res. 2001, 7, 3658s.
32. Hudkins, R. L.; Knight, E., Jr. Fused pyrrolocarbazole. U.S. Patent 5,705,511, 1997.
33. Hudkins, R. L.; Park, C.-H. Synthesis of indeno[2,1-a]pyrrolo-[3,4-c]carbazole lactam regioisomers using ethyl cis-β-cyanoacrylate as a dienophile and lactam precursor. J. Heterocycl. Chem. 2003, 40, 135-142.
34. Kaneko, M.; Saito, Y.; Saito, H.; Matsumoto, T.; Matsuda, Y.; Vaught, J. L.; Dionne, C. A.; Angeles, T. S.; Glicksman, M. A.; Neff, N. T.; Rotella, D. P.; Kauer, J. C.; Mallamo, J. P.; Hudkins, R. L.; Murakata, C. Neurotrophic 3,9-bis [(alkylthiomethyl]- and -[bis(alkoxymethyl)]-K-252a derivatives. J. Med. Chem. 1997, 40, 1863-1869.
35. Synthesis of esters. In Carbonylation: Direct Synthesis of Carbonyl Compounds; Colquhoun, H. M., Thompson, D. J., Twigg, M. V., Eds.; Plenum Press: New York, 1991; pp 111-141.
36. Angles, T. S.; Steffler, C.; Bartlett, B. A.; Hudkins, R. L.; Stephens, R. M.; Kaplan, D. R.; Dionne, C. A. Enzyme linked immunosorbant assay for TrkA tyrosine kinase activity. Anal. Biochem. 1996, 236, 49-55.
37. Mohammadi, M.; McMahon, G.; Sun, L.; Tang, C.; Hirth, P.; Yeh, B. K.; Hubbard, S. R.; Schlessinger, J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997, 276, 955-960.
38. Mctigue, M. A.; Wickersham, J. A.; Pinko, C.; Showalter, R. E.; Parast, C. V.; Tempczyk-Russell, A.; Gehring, M. R.; Mroczkowski, B.; Kan, C. C.; Villafranca, J. E.; Appelt, K. Crystal Structure of the Kinase Domain of Human Vascular Endothelial Growth Factor Receptor 2: A Key Enzyme in Angiogenesis. Structure 1999, 7, 319-330.
39. Toledo, L. M.; Lydon, N. B. Structures of staurosporine bound to CDK2 and cPKA-new tools for structure-based design of protein kinase inhibitors. Curr. Biol. 1997, 5, 1551-1556.
40. Hudkins, R. L.; Iqbal, M.; Park, C.-H.; Goldstein, J.; Herman, J. L.; Shek, E.; Murakata, C.; Mallamo, J. P. Prodrug esters of the indolocarbazole CEP-751 (KT-6587). Bioorg. Med. Chem. Lett. 1998, 8, 1873-1876.
41. Ruggeri, B.; Singh, J.; Gingrich, D.; Angeles, T.; Albom, M.; Chang, H.; Robinson, C.; Hunter, K.; Dobrzanski, P.; Jones-Bolin, S.; Aimone, L.; Klein-Szanto, A.; Herbert, J.-M.; Bono, F.; Casellas, P.; Bourie, B.; Pili, R.; Isaacs, J.; Ator, M. A.; Hudkins, R.; Dionne, C.; Mallamo, J.; Vaught, J. CEP-7055: A novel, orally-active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent anti-angiogenic activity and anti-tumor efficacy in pre-clinical models. Cancer Res. 2003, 63, 5978-91.
42. (a) Vailhe, B.; Vittet, D.; Feige, J.-J. In vitro models of vasculogenesis and angiogenesis. Lab. Invest. 2001, 81, 439-452.
43. (b) Ilan, N.; Mahooti, S.; Madri, J. A. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J. Cell Sci. 1998, 111, 3621-3631.
44. (c) Brown, K. J.; Maynes, S. F.; Bezos, A.; Maguire, D. J.; Ford, M. D.; Parish, C. R. A novel in vitro assay for human angiogenesis. Lab. Invest. 1996, 75, 539-555.
45. (d) Nicosia, R. F.; Lin, Y. J.; Hazelton, D.; Qian, X. Endogenous regulation of angiogenesis in the rat aorta model. Role of vascular endothelial growth factor. Am. J. Pathol. 1997, 151, 1379-1386.
46. Ruggeri, B.; Singh, J.; Hudkins, R.; Gingrich, D.; Angeles, T.; Robinson, C.; Chang, H.; Hunter, K.; Dobrzanski, P.; Pritchard, S.; Vaught, J.; Dionne, C. CEP-7055: an orally-active VEGF-R kinase inhibitor with potent anti-angiogenic activity and anti-tumor efficacy against human tumor xenograft growth. Proc. Am. Assoc. Cancer Res. 2002, 43, 5347.
47. Ruggeri, B. A.; Robinson, C.; Angeles, T.; Wilkinson, J.; Clapper, M. L. The chemopreventive agent Olipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograph growth. Clin. Cancer Res. 2002, 8, 267-274.
48. Rotin, D.; Margolis, B.; Mohammadi, M.; Daly, R. J.; Daum, G.; Li, N.; Fischer, E. F.; Burgess, W. H.; Ullrich, A.; Schlessinger, J. SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C-γ. EMBO J. 1992, 11, 559-567.